Patents by Inventor Yuegang Zhang

Yuegang Zhang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230331712
    Abstract: The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.
    Type: Application
    Filed: November 22, 2022
    Publication date: October 19, 2023
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ali Keshavarz-Shokri, Beili Zhang, Tim Edward Alcacio, Elaine Chungmin Lee, Yuegang Zhang, Mariusz Krawiec
  • Publication number: 20230207510
    Abstract: This application discloses a chip packaging module and an electronic device. The disclosed chip packaging module includes a bearing plate, a die, conductive adhesive, a connection reinforcing part, and a packaging layer, where the die is electrically connected to the bearing plate through the conductive adhesive, the connection reinforcing part is connected to the bearing plate, at least part of the connection reinforcing part is disposed in the conductive adhesive, and the packaging layer is disposed on the bearing plate, and covers the die, the conductive adhesive, and the connection reinforcing part.
    Type: Application
    Filed: February 21, 2023
    Publication date: June 29, 2023
    Inventors: Yuegang ZHANG, Lei LUO
  • Patent number: 11578062
    Abstract: The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.
    Type: Grant
    Filed: November 25, 2020
    Date of Patent: February 14, 2023
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Ali Keshavarz-Shokri, Beili Zhang, Tim Edward Alcacio, Elaine Chungmin Lee, Yuegang Zhang, Mariusz Krawiec
  • Patent number: 11485739
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: November 1, 2022
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
  • Publication number: 20210340128
    Abstract: The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.
    Type: Application
    Filed: November 25, 2020
    Publication date: November 4, 2021
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ali Keshavarz-Shokri, Beili Zhang, Tim Edward Alcacio, Elaine Chungmin Lee, Yuegang Zhang, Mariusz Krawiec
  • Publication number: 20210032255
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.
    Type: Application
    Filed: August 17, 2020
    Publication date: February 4, 2021
    Inventors: Jean-Damien CHARRIER, Christopher John DAVIS, Damien FRAYSSE, Gorka ETXEBARRIA I JARDI, Simon PEGG, Francoise PIERARD, Joanne PINDER, John STUDLEY, Carl ZWICKER, Tapan SANGHVI, Michael WALDO, Ales MEDEK, David Matthew SHAW, Maninder PANESAR, Yuegang ZHANG, Naziha ALEM
  • Patent number: 10906891
    Abstract: The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.
    Type: Grant
    Filed: August 23, 2018
    Date of Patent: February 2, 2021
    Assignee: Vertex Pharmaceuticals Incoporated
    Inventors: Ali Keshavarz-Shokri, Beili Zhang, Tim Edward Alcacio, Elaine Chungmin Lee, Yuegang Zhang, Mariusz Krawiec
  • Patent number: 10826125
    Abstract: The invention relates to a mono-nuclei cationized magnesium salt, a preparation method and applications thereof. The mono-nuclei cationized magnesium salt has a chemical formula of MgRnMX4-mYm, wherein R is a non-aqueous solvent molecule, M includes Al3+ and/or B3+, X and Y respectively include halide ion and halogenoid ion, n is any one integer selected in the range of 0˜6, and m is any one integer selected in the range of 0-4. The mono-nuclei cationized magnesium salt provided by the invention has a simple structure and excellent electrochemical properties, and the preparation method thereof features low cost, integrated synthesis, accessible raw materials, simple preparation process, and simple scaled production.
    Type: Grant
    Filed: December 28, 2015
    Date of Patent: November 3, 2020
    Assignee: Suzhou Institute of Nano-Tech and Nano-Bionics (Sinano), Chinese Academy of Sciences
    Inventors: Yuegang Zhang, Wanfei Li
  • Patent number: 10815239
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: October 27, 2020
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
  • Patent number: 10716789
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Grant
    Filed: July 18, 2018
    Date of Patent: July 21, 2020
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael P. Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Patent number: 10640884
    Abstract: A black phosphorus crystal having a high photoelectric response rate, a two-dimensional black phosphorus PN junction, and preparation method and use thereof. The black phosphorus crystal is a single crystal with a spatial point group Cmca (No. 64), cell parameters a=3.2-3.4 ?, b=10.4-10.6 ?, c=4.3-4.5 ?, and an interlayer spacing of 4-6 ?, and is characterized by a high photoelectric response rate, an adjustable semiconductor type, and the like. The two-dimensional black phosphorus PN junction includes a two-dimensional black phosphorus film, a first area of the film forming an n-type semiconductor by n-type doping, a second area of the film is maintained as a p-type semiconductor, and the first area is adjacent to the second area, to enable the n-type semiconductor to be combined with the p-type semiconductor to form the PN junction. The two-dimensional black phosphorus PN junction has properties such as a unidirectional conductivity, or a special photovoltaic effect.
    Type: Grant
    Filed: December 28, 2016
    Date of Patent: May 5, 2020
    Assignee: Suzhou Institute of Nano-Tech and Nano-Bionics (Sinano), Chinese Academy of Sciences
    Inventors: Kai Zhang, Yuegang Zhang, Yijun Xu
  • Patent number: 10439213
    Abstract: The invention provides a nitrogen-doped graphene coated nano sulfur positive electrode composite material, a preparation method, and an application thereof. The composite material includes: an effective three-dimensional conductive network formed by overlapping of nitrogen-doped graphenes, and nano sulfur particles coated by nitrogen doped graphene layers evenly. The preparation method includes: dispersing nitrogen-doped graphenes in a liquid-phase reaction system including at least sulfur source and acid, and depositing nano sulfur particles by an in-situ chemical reaction of the sulfur source and the acid, thereby preparing the positive electrode composite material. The positive electrode composite material of the invention has a high conductivity, a high sulfur utilization rate, and a high rate, thereby restraining the dissolution and shuttle effect in the lithium sulfur batteries, and enhancing the cyclic performance of the batteries.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: October 8, 2019
    Assignee: SUZHOU INSTITUTE OF NANO-TECH AND NANO-BIONICS, CHINESE ACADEMY OF SCIENCE
    Inventors: Yuegang Zhang, Yongcai Qiu, Wanfei Li, Guizhu Li, Yuan Hou, Meinan Liu, Lisha Zhou, Fangmin Ye, Hongfei Li
  • Publication number: 20190270728
    Abstract: The present invention relates to solid forms of (R)-1-(2,2-difluorobenzo[d][1,3 ]dioxol-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide (Compound 1) in substantially crystalline form (Form A) or amorphous form, pharmaceutical compositions thereof, and methods of treatment therewith.
    Type: Application
    Filed: August 23, 2018
    Publication date: September 5, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Ali Keshavarz-Shokri, Beili Zhang, Tim Edward Alcacio, Elaine Chungmin Lee, Yuegang Zhang, Mariusz Krawiec
  • Publication number: 20190256516
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.
    Type: Application
    Filed: November 15, 2018
    Publication date: August 22, 2019
    Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
  • Patent number: 10273233
    Abstract: Polymorphic forms of Compound (1) or a pharmaceutically acceptable salt thereof, wherein Compound (1) is represented by the following structural formula: include Hydrate 2 of Compound (1), Hydrate 3 of Compound (1), Form A of Compound (1), Form B of Compound (1), Form C of Compound (1), Form D of Compound (1), and amorphous Compound (1). Such polymorphic forms are useful for treating influenza, inhibiting the replication of influenza viruses, or reducing the amount of influenza viruses in a biological sample or in a subject.
    Type: Grant
    Filed: November 9, 2017
    Date of Patent: April 30, 2019
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Luc J. Farmer, Michael John Boyd, Dean Shannon, Michael Waldo, Kwame W. Nti-Addae, Yuegang Zhang
  • Publication number: 20190055668
    Abstract: A black phosphorus crystal having a high photoelectric response rate, a two-dimensional black phosphorus PN junction, and preparation method and use thereof. The black phosphorus crystal having a high photoelectric response rate is a single crystal with a spatial point group Cmca (No. 64), cell parameters a=3.2-3.4 ?, b=10.4-10.6 ?, c=4.3-4.5 ?, and an interlayer spacing of 4-6 ?, and is characterized by a high photoelectric response rate, an adjustable semiconductor type, and the like. Its preparation method is simple with a mild condition, a high yield, a low cost, and less pollution. The two-dimensional black phosphorus PN junction comprises a two-dimensional black phosphorus film, a first area of the film forming an n-type semiconductor by n-type doping, a second area of the film is maintained as a p-type semiconductor, and the first area is adjacent to the second area, to enable the n-type semiconductor to be combined with the p-type semiconductor to form the PN junction.
    Type: Application
    Filed: December 28, 2016
    Publication date: February 21, 2019
    Inventors: Kai Zhang, Yuegang Zhang, Yijun Xu
  • Publication number: 20190038615
    Abstract: The present invention relates to pharmaceutical compositions comprising a compound of Formula I in combination with one or both of a Compound of Formula II and/or a Compound of Formula III. The invention also relates to solid forms and to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis.
    Type: Application
    Filed: February 19, 2018
    Publication date: February 7, 2019
    Applicant: Vertex Pharmaceuticals Incorporated
    Inventors: Fredrick F. Van Goor, Rossitza Gueorguieva Alargova, Tim Edward Alcacio, Sneha G. Arekar, Steven C. Johnston, Irina Nicolaevna Kadiyala, Ali Keshavarz-Shokri, Mariusz Krawiec, Elaine Chungmin Lee, Ales Medek, Praveen Mudunuri, Mark Jeffrey Sullivan, Noreen Tasneem Zaman, Beili Zhang, Yuegang Zhang, Gregor Zlokarnik
  • Patent number: 10160760
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and solid forms of the compounds of this invention. The compounds of this invention have formula I-A or I-B: wherein the variables are as defined herein.
    Type: Grant
    Filed: December 5, 2014
    Date of Patent: December 25, 2018
    Assignee: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jean-Damien Charrier, Christopher John Davis, Damien Fraysse, Gorka Etxebarria I Jardi, Simon Pegg, Francoise Pierard, Joanne Pinder, John Studley, Carl Zwicker, Tapan Sanghvi, Michael Waldo, Ales Medek, David Matthew Shaw, Maninder Panesar, Yuegang Zhang, Naziha Alem
  • Publication number: 20180325897
    Abstract: The present invention relates to compositions and co-crystals each comprising a compound of formula I having the structure: wherein each of R1 and R2 is H or 2H and a co-crystal former selected from adipic acid, citric acid, fumaric acid, maleic acid, succinic acid, or benzoic acid. Also within the scope of this invention are methods of making and using the same.
    Type: Application
    Filed: July 18, 2018
    Publication date: November 15, 2018
    Inventors: Kwame Wiredu Nti-Addae, Simon Adam O'Neil, Yuegang Zhang, Michael Waldo, Praveen Mudunuri, Bin Song, John Gregg Van Alsten, Mark Strohmeier, Kathy Stavropoulos, Irina Nikolaevna Kadiyala, Mettachit Navamal
  • Publication number: 20180316059
    Abstract: The invention relates to a mono-nuclei cationized magnesium salt, a preparation method and applications thereof. The mono-nuclei cationized magnesium salt has a chemical formula of MgRnMX4-mYm, wherein R is a non-aqueous solvent molecule, M includes Al3+ and/or B3+, X and Y respectively include halide ion and halogenoid ion, n is any one integer selected in the range of 0˜6, and m is any one integer selected in the range of 0˜4. The mono-nuclei cationized magnesium salt provided by the invention has a simple structure and excellent electrochemical properties, and the preparation method thereof features low cost, integrated synthesis, accessible raw materials, simple preparation process, and simple scaled production.
    Type: Application
    Filed: December 28, 2015
    Publication date: November 1, 2018
    Inventors: Yuegang Zhang, Wanfei Li